Estriol has no FDA-approved single-agent product in the United States. There is no branded estriol dose to anchor on, no US manufacturer schedule, no average trial patient to titrate toward. The European literature was built around vaginal pessaries and oral tablets at fixed strengths, and even those studies were not picked for your baseline E2, your age at menopause, your endometrial history, whether your symptoms are predominantly vaginal and urogenital or systemic, or whether you respond to estradiol the way the average study participant did.
That is the work a compounding pharmacy does. Estriol in the US exists almost entirely as a compounded preparation: vaginal cream and suppositories for GSM at strengths the European brands do not cover, oral troches and capsules for systemic symptoms, and Bi-Est blends (estriol plus estradiol) where the ratio is chosen for that patient rather than fixed by a manufacturer. A prescriber who knows your chart can shift the E3:E2 ratio, drop the systemic dose, swap route from oral to vaginal when only urogenital tissue needs treatment, and leave out preservatives or excipients you do not tolerate. Estriol's well studied evidence base is in vaginal use for genitourinary symptoms; systemic and Bi-Est dosing rests on lower-tier evidence and individual response, which is exactly the situation a patient-specific prescription is built for.
This is what pharmacy looked like before mass manufacturing. A doctor wrote the prescription, a pharmacist prepared it for that patient, and the label named them both. Compounded estriol is that older arrangement, kept honest by modern oversight.
In brief
Estriol Explained
Estriol (E3) is one of three human estrogens (alongside estradiol/E2 and estrone/E1) 2. It is a weaker estrogen than estradiol and is the dominant estrogen circulating during pregnancy, where it is made by the placenta.
Outside the US, estriol has been used for decades as a prescription medicine for menopausal vaginal atrophy and related symptoms; brands such as Ovestin are sold in Europe 30. In the United States, estriol is not FDA-approved as a drug, no branded estriol product is marketed in the US, and the only legal way to obtain it is via 503A compounding pharmacies on a patient-specific prescription.
Major US menopause societies (NAMS, the Endocrine Society, NASEM, and ACOG) have raised concerns about how compounded estriol, especially in Bi-Est and Tri-Est combinations, is marketed to consumers as a 'safer' or 'natural' alternative to FDA-approved estradiol 252627. The available evidence does not support those marketing claims. RonanRx prepares estriol only on a patient-specific prescription written by a licensed doctor for an identified patient and does not promote cBHRT marketing language 1.
Dominant estrogen during pregnancy (placental product); minor circulating estrogen outside pregnancy
Receptor preference
Binds both ERα and ERβ but with markedly lower affinity than estradiol; short residence time on the receptor gives it weak agonist behavior at usual physiologic concentrations
FDA-approval status (United States)
NOT FDA-approved. No branded estriol product is marketed in the US. Estriol is available in the US only through 503A compounding.
Approval outside the US
Marketed in many European countries as Ovestin and similar brands for vaginal atrophy and menopausal symptoms; available in the United Kingdom, Netherlands, Germany, and elsewhere
Compounded under
503A, patient-specific prescription only
Common compounded forms
Vaginal cream, vaginal suppository / pessary, oral tablet, troche, and compounded combinations such as Bi-Est (estriol + estradiol) or Tri-Est (estriol + estradiol + estrone)
cBHRT context
Major US menopause and endocrine bodies (NAMS, Endocrine Society, NASEM, ACOG) have specifically criticized marketing of compounded bioidentical hormone therapy, including Bi-Est and Tri-Est, that claims estriol-containing preparations are 'safer' than FDA-approved estradiol products. Evidence does not support that claim.
Prescription review
Patient-Specific Prescription Only
Estriol on this page is a 503A compounded preparation. Every dose is made on a prescription, for a named patient, by a licensed pharmacist. It is not a stocked, mass-manufactured product.
Made to order, not off a shelf. No batch sits in a warehouse waiting for buyers. Your prescription is what triggers the prep.
Named-patient label. The bottle carries your name. The batch records carry your prescription.
Dose, strength, and route chosen for you. A prescriber who knows your chart decides what gets compounded, not a manufacturer who set the strength for a trial population.
Licensed pharmacist on the hook. A real person, with a license that can be pulled, signs off on every prep. State inspectors check the facility.
Compounded drugs are not FDA-approved. They should not be evaluated using branded-drug trial data. Availability varies by state and prescribed medication.
A research-use-only website ships a vial from a warehouse. There is no prescription, no pharmacist, no facility inspection, and no way to recall the product if something is wrong with it. If the vial is mislabeled, contaminated, or under-potent, there is nobody whose license is at stake.
A 503A compounding pharmacy is the other thing. Your doctor writes the prescription. A licensed pharmacist, whose name is on the label, prepares the medicine in a facility the state inspects. If something goes wrong, there is a person and a license on the hook, and a documented chain of custody on every lot. That accountability is what makes it safe.
What it is
What is Estriol?
Estriol (E3) is a steroid hormone produced naturally in the human body. Chemically it is 16α-hydroxy-estradiol, a metabolite of estradiol with an additional hydroxyl group at position 16α 2. Outside pregnancy, plasma estriol concentrations are low (typically <80 pg/mL), and most circulating E3 is derived from peripheral conversion of estradiol and estrone 1.
During pregnancy estriol becomes the dominant circulating estrogen. The placenta synthesizes large amounts of estriol from dehydroepiandrosterone sulfate (DHEAS) produced by the fetal adrenal gland and 16α-hydroxylated in the fetal liver, so maternal serum estriol rises from picograms per milliliter to nanograms per milliliter over the course of gestation 2. Maternal unconjugated estriol was historically used in clinical practice as a marker of fetoplacental well-being and remains a component of the second-trimester triple/quadruple screen for fetal aneuploidy.
Outside pregnancy, estriol is sometimes referred to as a 'weak' estrogen because its affinity for the estrogen receptor, and especially its receptor residence time, is much lower than estradiol's 12. Pharmacologically it is still an estrogen agonist; with continuous exposure at therapeutic doses, its biological effects are qualitatively similar to those of other estrogens, just less potent.
How it works
How Estriol Works
Class
Bioidentical estrogen (weak)
First studied
1930s
Common forms
Bi-Est cream, troche, vaginal preparations
Compounding category
503A, patient-specific prescription
Estriol binds the two classical nuclear estrogen receptors, ERα and ERβ, and triggers the same general transcriptional machinery as estradiol. The difference is quantitative: estriol's binding affinity for ER is roughly one order of magnitude lower than estradiol's, and its receptor residence time is much shorter 21. At physiologic non-pregnant concentrations this short residence translates into weaker estrogenic effect. At sustained therapeutic doses, estriol behaves as a full estrogen agonist on target tissues.
Selectivity between ERα and ERβ is modest and concentration-dependent 1. Marketing claims that estriol is a clean 'ERβ-selective' estrogen and therefore inherently safer than estradiol have not been supported in the controlled clinical literature 2526.
Vaginal estriol acts predominantly on local ER in the vaginal epithelium, urethra, trigone, and vulvar tissues, the targets of genitourinary syndrome of menopause (GSM). At low vaginal doses, systemic absorption is small relative to oral therapy, which is why low-dose vaginal estriol has been adopted in European practice as a local therapy for GSM with limited systemic estrogenic exposure 21221.
Research history
Estriol Research History
Estriol was characterized as a third human estrogen in the 1930s 28. European clinical use for menopausal symptoms began in the 1960s and 1970s under brand names such as Ovestin (Organon) and continued through subsequent decades in oral and vaginal formulations 12.
Schiff and colleagues' work in the 1980s and a sequence of European and Japanese trials in the 1990s and 2000s established the dose ranges used clinically for oral and vaginal estriol in menopausal symptoms 121328. A line of work culminating in Granberg 2002 documented that oral estriol at typical European doses does not appear to stimulate the endometrium meaningfully when used as monotherapy at low dose 141819.
The vaginal estriol literature accelerated in the 2000s and 2010s with multiple randomized trials and head-to-head comparisons in postmenopausal vaginal atrophy and GSM, including ultra-low-dose 50 μg vaginal gel formulations 281617. The 2016 Cochrane review by Lethaby and colleagues 21 consolidated this evidence and concluded that low-dose vaginal estrogens (including vaginal estriol) are effective for GSM with limited systemic absorption 20.
Outside menopausal medicine, the most consequential modern estriol literature is Rhonda Voskuhl's multiple sclerosis program at UCLA 28. The original 2002 open-label pilot in 10 women with relapsing-remitting or secondary-progressive MS reported a substantial reduction in gadolinium-enhancing brain lesions during pregnancy-range estriol dosing 3. Mechanistic follow-up 4 documented immunologic shifts. The 2016 placebo-controlled phase 2 trial of oral estriol 8 mg/day added to glatiramer acetate in 158 women with RRMS 5 demonstrated a modest reduction in annualized relapse rate at 12 months that did not persist at 24 months, and follow-on neuroimaging 6 and neurofilament-light-chain 7 analyses described subgroup signals. To date this remains the only well-controlled trial of high-dose oral estriol for an autoimmune disease, and the effect is best characterized as modest.
On the regulatory and societal side, the 2010s and 2020s saw a sequence of major US position statements specifically addressing compounded bioidentical hormone therapy: ACOG Committee Opinion 532 (2012) 27, the NAMS 2017 hormone therapy position statement 25, Pinkerton & Pickar 2016 29, the 2020 NASEM consensus report on cBHRT 26, and Pinkerton 2022 3028. All of these explicitly addressed estriol-containing compounded preparations and concluded that marketing claims of superior safety or 'natural' advantage are not supported by the evidence and that prescribing should be patient-specific rather than driven by direct-to-consumer marketing.
Timeline
Estriol Timeline
1930sEstriol characterized as a third human estrogen alongside estradiol and estrone
1960s, 1980sEuropean clinical use of oral and vaginal estriol (Ovestin, Synapause) for menopausal symptoms; foundational pharmacology and dose-finding work 12
1994Henriksson et al 15. publish multicenter comparison of estradiol vaginal ring vs estriol vaginal pessaries for urogenital atrophy
1998Head publishes 'Estriol: safety and efficacy' review in Alternative Medicine Review, summarizing European estriol literature for North American audience 1
2000Takahashi et al 1213. publish two reports on oral estriol for postmenopausal symptoms (Maturitas; Human Reproduction)
2002Sicotte et al. publish open-label pilot of oral estriol 8 mg/day in 10 women with multiple sclerosis (Annals of Neurology); Granberg et al 314. publish endometrial-safety study of oral estriol
2003Soldan et al 4. publish immune-modulation mechanism data from the Sicotte pilot population
2005Kuhl publishes comprehensive review 'Pharmacology of estrogens and progestogens: influence of different routes of administration' (Climacteric) 2
2016Voskuhl et al. publish phase 2 trial of estriol + glatiramer acetate in relapsing-remitting MS (Lancet Neurology); Caruso et al 5. publish ultra-low-dose vaginal estriol gel quality-of-life trial; Lethaby et al 1621. Cochrane review of local vaginal estrogen for atrophy
2017NAMS 2017 hormone therapy position statement explicitly addresses cBHRT including estriol-containing preparations; Caruso 2017 ultralow topical estriol in pelvic-organ-prolapse population 2517
2018MacKenzie-Graham et al 6. publish voxel-based morphometry analysis of estriol-treated MS patients showing localized neuroprotection signal
2020NASEM publishes 'The Clinical Utility of Compounded Bioidentical Hormone Therapy' consensus report; Hirschberg et al 2619. publish ultra-low-dose vaginal estriol gel in breast-cancer survivors on aromatase inhibitors
2022Pinkerton publishes 'Concerns About Compounded Bioidentical Menopausal Hormone Therapy' (Cancer Journal); Voskuhl et al 307. report decreased neurofilament-light-chain in estriol-treated MS
2023Crandall et al 24. JAMA review 'Management of Menopausal Symptoms' summarizes evidence for vaginal estrogens including estriol in GSM
Natural role
Biological Role of Estriol
Estriol is the dominant circulating estrogen during human pregnancy. The placenta cannot synthesize estriol on its own; it depends on a fetoplacental unit in which the fetal adrenal gland makes DHEA-sulfate, the fetal liver 16α-hydroxylates it, and the placenta then aromatizes that substrate to estriol 2. This anatomical dependency made maternal serum unconjugated estriol a useful historical marker of fetal-placental function, low maternal estriol can indicate fetal compromise, placental insufficiency, or anencephaly. In current US obstetric practice, unconjugated estriol remains a component of the second-trimester multiple-marker screen for trisomy 21, trisomy 18, and open neural-tube defects, where low maternal E3 is one of the contributing markers.
Outside pregnancy, estriol is a minor circulating estrogen. Most estriol in non-pregnant adults derives from peripheral metabolism of estradiol and estrone rather than from de novo ovarian secretion 1. Endogenous postmenopausal estriol concentrations are very low.
The clinical relevance of estriol outside pregnancy is therefore almost entirely pharmacologic, exogenous administration for menopausal symptoms (predominantly vaginal atrophy / GSM in European practice), for compounded combination 'Bi-Est' and 'Tri-Est' menopausal hormone therapy preparations in the US, and as an investigational adjunct in autoimmune disease.
Clinical contexts studied
Clinical Contexts for Estriol
Genitourinary syndrome of menopause (GSM) / vulvovaginal atrophy well studied
Well studied outside the US; vaginal estriol is a first-line local therapy in European practice.
Multiple randomized trials and a 2016 Cochrane systematic review 21 support low-dose vaginal estriol (cream, suppository/pessary, ring, or ultra-low-dose gel) for the symptoms of postmenopausal vaginal atrophy, dryness, dyspareunia, urgency, and recurrent UTI 1522. Ultra-low-dose 50 μg estriol vaginal gel has been studied in healthy postmenopausal women 16, in women after surgery for pelvic-organ prolapse 17, in coital pain populations 18, and in breast-cancer survivors on aromatase inhibitors 19. Vaginal estriol combined with lactobacilli has been studied for quality of life in endocrine-treated breast cancer 20. Systemic absorption from low-dose vaginal estriol is limited, and endometrial stimulation appears minimal at standard dosing 1421. In the US, vaginal estriol is available only through 503A compounding because no FDA-approved estriol product exists 24.
Menopausal vasomotor symptoms (oral estriol) well studied
Studied in European and Japanese trials; less effective than estradiol; not first-line in current US guidelines.
Oral estriol has been studied for menopausal symptoms including hot flushes and mood disturbance, predominantly in European and Japanese populations 1213. Typical European oral doses (1, 8 mg/day) reduce some menopausal symptoms but are generally considered less potent than oral estradiol 2124. Endometrial safety at standard European oral doses appears acceptable 14, although high or sustained oral dosing reaches receptor occupancies comparable to other estrogens and conventional unopposed-estrogen risks should be assumed unless specifically refuted 25. US menopause guidelines do not recommend oral estriol as a first-line vasomotor therapy.
Common compounded use in US practice; major US menopause and endocrine bodies have specifically criticized claims that estriol-containing combinations are 'safer' than FDA-approved estradiol.
In the United States, where no FDA-approved estriol product is marketed, compounded combinations of estriol with estradiol (Bi-Est, typically 80% estriol / 20% estradiol) or estriol + estradiol + estrone (Tri-Est) are commonly prepared as menopausal hormone therapy in topical creams, troches, or pellets 3132. The pharmacologic rationale offered in cBHRT marketing, that estriol is a uniquely 'safe' or 'natural' estrogen, has been specifically and repeatedly criticized by ACOG (Committee Opinion 532) 27, NAMS (2017 position statement) 25, the Endocrine Society / Pinkerton & Pickar 2016 2928, the 2020 NASEM consensus report 26, and Pinkerton 2022 30. The consensus across these bodies is that compounded estriol-containing menopausal HT should be reserved for patient-specific clinical needs that an FDA-approved estradiol product cannot meet (e.g., true documented allergy to a non-active ingredient, dose that is not commercially available), not used as a direct-to-consumer 'safer alternative.'
Investigational adjunctive use; one well-designed phase 2 trial with modest effect.
The Voskuhl program at UCLA has been the principal source of MS evidence. The 2002 open-label pilot 3 in 10 women reported reduction in gadolinium-enhancing lesions on oral estriol 8 mg/day. Mechanistic immune studies 4 and preclinical EAE studies 8910 supported plausibility. The 2016 randomized, placebo-controlled phase 2 trial added oral estriol 8 mg/day to glatiramer acetate in 158 women with RRMS 5 and reported a modest reduction in annualized relapse rate at 12 months that did not persist at 24 months 11. Follow-up MRI 6 and neurofilament-light-chain 7 analyses describe additional subgroup signals. No pivotal trial has been completed. The clinical context is one well-designed phase 2 trial with modest effect; estriol is not an FDA-approved MS therapy.
Recurrent urinary tract infection in postmenopausal women well studied
Local vaginal estrogen (including estriol) reduces recurrent UTI in postmenopausal women.
Postmenopausal genitourinary atrophy is associated with recurrent UTI, and local vaginal estrogen reduces the recurrence rate in placebo-controlled trials. The Lethaby 2016 Cochrane review and follow-up reviews of postmenopausal UTI management identify local vaginal estrogens, including estriol formulations in European studies, as effective for UTI recurrence reduction 2123. The mechanism is restoration of vaginal epithelial maturation, vaginal pH, and lactobacillus colonization 20.
Off-label use
Off-Label Uses of Estriol
Pregnancy fetal-monitoring marker (historical clinical use) well studied
Historical use, now largely superseded.
Maternal serum or urinary unconjugated estriol was used historically as a marker of fetoplacental well-being. In current US obstetric practice it remains a component of the second-trimester multiple-marker (triple/quad) screen for fetal aneuploidy and open neural-tube defects, but cell-free fetal DNA and other markers have largely replaced E3 monitoring for routine fetal-well-being assessment. This is a diagnostic use of endogenous estriol, not a therapeutic use of exogenous estriol 2.
Compounded use
Compounded Estriol (503A)
Because no FDA-approved estriol product is marketed in the US, every estriol prescription in the US is filled either via importation from Europe under specific conditions or, far more commonly, by a 503A compounding pharmacy 272630. This is structurally different from many other compounded substances, where compounding is an alternative to an FDA-approved product. For estriol, compounding is the primary route of legal US availability.
RonanRx prepares compounded estriol on a patient-specific prescription written by a licensed prescribing physician for an identified patient, consistent with section 503A of the Federal Food, Drug, and Cosmetic Act 33. Common preparations include vaginal cream, vaginal suppository, oral tablet or troche, and combination products such as Bi-Est and Tri-Est.
RonanRx does not market compounded estriol-containing menopausal hormone therapy as 'safer' or 'more natural' than FDA-approved estradiol products 29. The major US menopause and endocrine bodies, ACOG, NAMS, the Endocrine Society, and the National Academies (NASEM), have explicitly stated that such marketing claims are not supported by the available evidence 25. Compounded estriol is appropriate when the prescribing physician documents a patient-specific clinical need (excipient sensitivity, dose not commercially available, vaginal formulation not commercially available in the US), not as a direct-to-consumer substitute for FDA-approved therapy 28.
Formulations and routes
Estriol Formulations and Routes
Form
Concentration
Description
Vaginal cream
0.5, 1 mg per gram (typical European labeling); ultra-low-dose 50 μg/g formulations studied in clinical trials
Applied intravaginally for GSM / vulvovaginal atrophy; the route with the strongest controlled evidence base21161719
Vaginal suppository / pessary
0.5 mg per pessary in the European literature (e.g., Henriksson 1994 used 0.5 mg estriol pessaries)
Doses listed reflect published clinical-trial protocols and European labeling for products that are not FDA-approved in the United States. They are not RonanRx prescribing recommendations. The prescribing doctor selects route, dose, and frequency based on the patient's clinical context, indication, and goals.
Doses listed should not be presented to patients as instructions. Patient instructions originate from the prescribing physician's prescription, not from this educational page.
Doses listed are literature context, not patient instructions. Dosing decisions are made by the prescribing doctor and tailored to the individual patient.
Safety
Estriol Safety
Safety overview
Estriol is an estrogen. Its safety profile shares the class-level considerations of other systemic estrogens, venous thromboembolism, stroke, gallbladder disease, breast and endometrial effects with sustained systemic exposure, and these should be assumed at therapeutic systemic doses unless directly refuted by trial data 25230. Marketing claims that estriol is intrinsically 'safer' or 'natural' relative to FDA-approved estradiol are not supported by the available evidence and have been specifically rejected by ACOG, NAMS, the Endocrine Society, and NASEM 272926.
Low-dose vaginal estriol delivers limited systemic absorption and is generally well tolerated in the published trials. Even at low vaginal doses, current US guidance treats vaginal estrogens in women with a history of breast cancer as a shared-decision discussion with the treating oncologist 191617. Endometrial safety at low-dose vaginal estriol monotherapy appears acceptable in the published literature 1421, although the lack of a US-labeled product means there is no FDA-approved endometrial-monitoring schedule for the formulations actually dispensed in the US 28.
Contraindications
By class, contraindications are those that apply to all systemic estrogen therapy: known or suspected estrogen-dependent malignancy (notably breast cancer, treated as a relative contraindication requiring oncology involvement), known or suspected pregnancy outside the specific obstetric context, active or recent venous thromboembolism, active arterial thromboembolic disease (recent stroke, MI), undiagnosed abnormal genital bleeding, severe active hepatic disease, and known hypersensitivity to a component of the preparation 252. The absence of a US-approved product means there is no FDA-labeled US contraindications list for estriol specifically; the prescribing physician applies the class-level considerations.
Drug interactions
Estriol shares the metabolic and binding considerations of other estrogens: hepatic CYP3A4-mediated metabolism (and therefore interactions with CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and St John's wort, and CYP3A4 inhibitors), competition with thyroid binding globulin and corticosteroid binding globulin that can alter free hormone levels, and modest effects on coagulation factors at systemic exposure. The clinical magnitude of these interactions for low-dose vaginal estriol is small but not zero 2. The prescribing physician's interaction review applies.
Adverse events
In the published vaginal estriol trials, reported adverse events have been mild and predominantly local, vaginal irritation, application-site discomfort, transient discharge, with low rates of systemic estrogenic symptoms 1617. In oral estriol trials at European menopausal doses, breast tenderness, headache, and breakthrough bleeding have been reported at frequencies comparable to other oral estrogens 121318. In the Voskuhl MS phase 2 trial at 8 mg/day, irregular menses was the most commonly reported adverse event 5.
Serious estrogen-class adverse events, venous thromboembolism, stroke, endometrial hyperplasia / cancer with sustained unopposed systemic dosing, breast effects, should be assumed possible at any systemic dose absent direct evidence to the contrary 252619. The low-dose-vaginal-estriol literature reports endometrial safety at standard dosing 1421 but is not the same as long-term high-dose oral data.
Monitoring
Monitoring Estriol Therapy
Monitoring follows the prescribing physician's plan and the indication. For low-dose vaginal estriol used for GSM, routine biochemical monitoring is not required; symptom response and any unexpected vaginal bleeding are the principal clinical signals, with prompt evaluation of any postmenopausal bleeding 2125.
For systemic (oral or compounded transdermal) estriol-containing menopausal HT, prescribers typically apply the monitoring framework of FDA-approved estradiol HT, periodic blood pressure, breast and pelvic examination per usual care guidelines, mammography per age-appropriate screening, evaluation of any abnormal bleeding, and reassessment of the risk/benefit balance at least annually 2524. Compounded preparations do not relieve any of these monitoring expectations.
Patients should report any unexpected vaginal bleeding, breast lump, leg swelling or pain (potential VTE), sudden severe headache or visual disturbance, or sudden weakness/numbness (potential stroke) to the prescribing physician promptly.
Special populations
Estriol in Special Populations
Pregnancy
Estriol is the dominant endogenous estrogen during pregnancy, but supplemental exogenous estriol given for menopausal or autoimmune indications is not appropriate during pregnancy. Estrogens used for menopausal hormone therapy or related indications are generally categorized as contraindicated in pregnancy 252. Where unconjugated estriol is measured during pregnancy, it is used as a diagnostic marker rather than administered.
Lactation
Estrogens can decrease the quantity and quality of breast milk and pass into milk in small amounts. Use during lactation is generally avoided absent a specific physician-determined need 25.
Pediatric
Estriol is not indicated and not studied for routine pediatric use.
Geriatric
Postmenopausal women are the predominant studied population for estriol. Risk/benefit considerations for systemic estrogen therapy in older women apply, including cardiovascular and venous thromboembolic risk 2524. Low-dose vaginal estriol for GSM has been studied in older postmenopausal cohorts including women in their 60s and 70s 1817.
Hepatic impairment
Severe active hepatic disease is a class contraindication to systemic estrogen therapy. For low-dose vaginal estriol, no formulation-specific hepatic-adjustment data exist in US labeling because no US labeling exists; prescriber judgment applies 2.
Evidence quality
Estriol Evidence Quality
Evidence quality varies sharply by indication. For low-dose vaginal estriol in GSM, the evidence is well developed: multiple randomized trials, a Cochrane systematic review 21, and a comprehensive JAMA narrative review 24 all support efficacy with limited systemic absorption 16.
For oral estriol in menopausal vasomotor symptoms, the evidence base is older and predominantly European/Japanese 121314, with limited US replication and no head-to-head superiority over FDA-approved oral or transdermal estradiol. US guidelines do not recommend oral estriol as first-line vasomotor therapy 252415.
For Bi-Est / Tri-Est compounded menopausal HT, there are no large randomized trials of the compounded combination itself; the cBHRT literature is dominated by position statements from the major menopause and endocrine bodies criticizing marketing claims 202730.
For multiple sclerosis, the entire human evidence base is one open-label pilot 3, one randomized phase 2 trial 5, and follow-up imaging/biomarker work 67. The phase 2 effect is best characterized as modest. No pivotal trial has been completed. Estriol is not an FDA-approved MS therapy 282926.
The absence of FDA approval is itself a critical feature of the US evidence landscape for estriol. The compound has not been through a US new-drug application; there is no FDA-reviewed labeling, no FDA-mandated endometrial safety data set for the formulations actually dispensed in the US, and no FDA pharmacovigilance pipeline. That structure shapes how compounded estriol can responsibly be used and how it should not be marketed 171819.
Oral estriol 8 mg/day added to glatiramer acetate reduced annualized relapse rate at 12 months (0.25 vs 0.37 with placebo) in women with RRMS; the difference did not persist at 24 months 5. Adverse events were balanced apart from irregular menses in the estriol arm.
In 6 women with RRMS, oral estriol 8 mg/day reduced gadolinium-enhancing brain lesions during treatment; effect reversed off-treatment and recurred on rechallenge 3. First in-human signal that pregnancy-range estriol could modulate MS activity.
Documented shifts in cytokine profile (reduced IFN-γ and TNF-α, increased IL-5 and IL-10) on estriol, consistent with immune-modulatory mechanism proposed from EAE models 4.
Voxel-based morphometry showed estriol treatment was associated with preserved gray-matter volume in specific cortical regions implicated in MS disability 6.
Low-dose vaginal estrogens, including estriol cream, pessary, and ring formulations, reduced symptoms of vaginal atrophy and improved vaginal cytology, with limited systemic absorption and limited endometrial stimulation in studied populations 21.
Ultra-low-dose (50 μg) estriol vaginal gel improved quality-of-life and sexual-function scores in naturally postmenopausal women with vaginal atrophy 16.
Phase II randomized double-blind placebo-controlled
61
12 weeks
Ultra-low-dose 50 μg estriol vaginal gel improved vulvovaginal atrophy in postmenopausal breast-cancer survivors on aromatase inhibitors 19. Systemic estriol exposure remained low. Use of vaginal estrogen in breast-cancer survivors remains a shared-decision discussion with the treating oncologist.
Combination of vaginal estriol and lactobacilli improved vaginal symptoms and quality of life in endocrine-treated breast cancer patients with vaginal atrophy 20.
Both the estradiol ring and 0.5 mg estriol vaginal pessaries improved urogenital atrophy symptoms and vaginal cytology with comparable efficacy; both were well tolerated 15.
Oral estriol at European doses improved climacteric symptoms; endometrial safety in studied population was acceptable; the comparator was not FDA-approved estradiol 12.
NASEM concluded that compounded bioidentical hormone therapy, including estriol-containing preparations, should be restricted to patient-specific medical needs that an FDA-approved product cannot meet, and that current marketing of cBHRT as 'safer' or 'natural' is not supported by evidence 26.
NAMS specifically addressed compounded estriol-containing hormone therapy and concluded that claims of superior safety vs FDA-approved estradiol are not supported by available evidence; compounded HT should be limited to patient-specific clinical needs 25.
Mechanism detail
Detailed Mechanism of Estriol
Mechanistically, estriol's short ER residence time means that, at low circulating levels, it occupies the receptor briefly and dissociates before completing the full transcriptional response that estradiol would. This kinetic difference, not a fundamentally different receptor, is the basis for its 'weak estrogen' classification 21. When estriol is administered continuously at higher doses, occupancy is sustained and the agonist response approaches that of other estrogens, including endometrial and breast tissue effects.
Some preclinical and older clinical work suggested that estriol given in a pulsed, brief-occupancy fashion might antagonize estradiol's effect on breast tissue 1; this hypothesis underpinned mid-century 'estriol therapy as breast protection' claims. Larger controlled clinical work has not confirmed that estriol is preferentially safe or protective at the breast at clinically used dosing schedules, and the 2017 NAMS position statement, the 2020 NASEM report on cBHRT, and ACOG Committee Opinion 532 all explicitly caution against marketing estriol-containing compounded products as 'safer' than FDA-approved estradiol 252627.
Mechanism studies relevant to multiple sclerosis (a non-classical indication for estriol) found that pregnancy-range estriol exposure is anti-inflammatory in experimental autoimmune encephalomyelitis (EAE), the principal MS animal model. Estrogen-receptor-α expression on astrocytes is required for the protective effect 89, and ERβ ligands are independently neuroprotective in disease-onset models 10. These mechanisms are biologically interesting and underpin the Voskuhl clinical program, but they describe MS biology rather than a 'safety' advantage for menopausal use.
Pharmacology
Estriol Pharmacokinetics & Pharmacodynamics
Pharmacokinetics
Oral estriol is rapidly absorbed and rapidly conjugated. First-pass hepatic conjugation to estriol-3-glucuronide and estriol-3-sulfate is extensive, so unconjugated oral estriol bioavailability is low and plasma half-life of the unconjugated parent is short 21. This first-pass conjugation is one reason European labeling has historically used relatively large oral doses (1, 8 mg/day) to achieve target tissue effect.
Vaginal estriol bypasses hepatic first pass. Even at low vaginal doses, local vaginal-tissue concentrations are high while systemic plasma concentrations remain modest 212. This is the pharmacokinetic basis for using low-dose vaginal estriol as a local GSM therapy with limited systemic exposure.
Plasma protein binding for estriol is moderate (lower than estradiol), and metabolism is via hepatic conjugation followed by enterohepatic recirculation and renal excretion. The pharmacokinetics of compounded troche and topical-cream Bi-Est / Tri-Est formulations are not well characterized in controlled studies 26, a gap repeatedly identified by NASEM and Pinkerton.
Pharmacodynamics
Pharmacodynamically estriol is a full estrogen agonist with reduced potency relative to estradiol because of shorter receptor residence time 21. At low local vaginal concentrations the dominant effect is restoration of vaginal epithelial maturation, vaginal pH, and lactobacillus colonization, the GSM endpoints. At higher systemic concentrations the full spectrum of estrogenic effects emerges, including potential endometrial proliferation if unopposed.
There is no compelling controlled-clinical evidence that estriol is a tissue-selective 'designer' estrogen with intrinsically lower breast or thrombotic risk than estradiol 252630. Marketing claims to that effect rely on selective interpretation of older preclinical work and are not endorsed by the major US menopause/endocrine bodies.
Comparative formulations
Comparing Estriol Formulations
Vaginal cream, vaginal pessary, and vaginal ring are the local routes used in the GSM literature. Direct head-to-head work 15 found that 0.5 mg estriol pessaries and a low-dose estradiol vaginal ring produced comparable improvement in urogenital atrophy symptoms and vaginal cytology 19. Newer ultra-low-dose 50 μg vaginal estriol gel formulations have been studied in multiple populations including breast-cancer survivors on aromatase inhibitors 161718.
Oral estriol is studied predominantly in European and Japanese trials at 1, 8 mg/day 121314; the 8 mg/day dose is also the dose used in the Voskuhl MS phase 2 trial 5. Oral estriol is not first-line for vasomotor symptoms in US guidelines 2524.
Compounded Bi-Est and Tri-Est creams and troches do not have controlled pharmacokinetic or efficacy data comparable to either FDA-approved estradiol products or the European estriol literature 2630. This evidence gap is one of the central findings of the NASEM consensus report on cBHRT.
Storage
Estriol Storage and Handling
Compounded estriol vaginal cream and topical preparations are typically stored at controlled room temperature per the dispensing pharmacy's labeling. Refer to the dispensing pharmacy's labeling for the specific preparation received, including beyond-use date.
RonanRx operations
Estriol Compounding & Operations
503A compounding
RonanRx prepares estriol under 503A on a patient-specific prescription written by a licensed prescribing physician for an identified patient, consistent with section 503A of the Federal Food, Drug, and Cosmetic Act 3328. Because no FDA-approved estriol product is marketed in the US, the 503A compounded form is the principal legal US route to the medication 272629.
Bulk drug substance is sourced from FDA-registered API suppliers, with ingredient suitability verified for the intended formulation pathway 25. Finished preparations follow USP <795> standards for non-sterile compounding (vaginal cream, oral tablet, troche). Each preparation carries a lot number tied to the prescription record.
RonanRx does not market estriol-containing menopausal HT as 'safer,' 'more natural,' or 'better' than FDA-approved estradiol products, consistent with the published positions of ACOG, NAMS, the Endocrine Society, and NASEM 2530.
Pharmacist review
Each prescription is reviewed by a licensed pharmacist before dispensing. Review covers prescribed strength, route, formulation suitability, patient-specific contraindications based on the prescription record, ingredient compatibility, and label accuracy.
Because estriol-containing HT can be substituted into a Bi-Est or Tri-Est combination that includes estradiol and/or estrone, the pharmacist confirms the prescribed combination, ratio, and strength against the prescription as written, with any clarifications routed back to the prescriber rather than resolved by the pharmacy unilaterally 33.
Quality and traceability
Every compounded preparation carries a lot number tied to the prescription record. Potency testing for compounded estrogen preparations follows USP <795> guidance with documentation retained per state board of pharmacy requirements. The NASEM report and Pinkerton position pieces specifically called out compounding-quality variability as a concern in the cBHRT marketplace 2630; operational discipline on assay, lot release, and recordkeeping is the appropriate response.
FAQ
Frequently Asked Questions About Estriol
Is estriol FDA-approved?
No. Estriol is not FDA-approved as a drug in the United States. No branded estriol product is marketed in the US. Estriol is available in the US only via 503A compounding on a patient-specific prescription2. (In Europe, estriol has been marketed for decades, Ovestin and similar, for menopausal vaginal atrophy.) Compounded drugs are not FDA-approved27261.
Is estriol safer than estradiol?
Major US menopause and endocrine bodies, ACOG, NAMS, the Endocrine Society, and NASEM, have specifically reviewed this question and concluded that the available controlled clinical evidence does not show a safety advantage for estriol-containing compounded preparations over FDA-approved estradiol products 272529. Marketing language asserting such an advantage is not supported by the literature. Estriol is a weaker estrogen by binding kinetics, but at therapeutic doses it is an estrogen agonist and class-level estrogen risks apply 282630.
What conditions has estriol been studied in?
Published controlled investigation has focused on genitourinary syndrome of menopause / vulvovaginal atrophy (vaginal cream, pessary, ring, and ultra-low-dose gel; multiple RCTs and a Cochrane review), menopausal symptoms in European/Japanese populations (oral estriol), recurrent UTI in postmenopausal women, and relapsing-remitting multiple sclerosis (one open-label pilot and one phase 2 randomized trial) 2116175. The strongest evidence base is for vaginal estriol in GSM 1912133.
What is Bi-Est? What is Tri-Est?
Bi-Est is a compounded combination of estriol with estradiol, most commonly 80% estriol and 20% estradiol by mass, usually prepared as a topical cream 2630. Tri-Est adds estrone 2528. These compounded combinations are widely marketed in the US as 'bioidentical' menopausal hormone therapy, but they are not FDA-approved, do not have controlled pharmacokinetic or efficacy data comparable to FDA-approved estradiol products, and have been specifically reviewed and criticized by ACOG, NAMS, the Endocrine Society, and NASEM when marketed as 'safer' or 'more natural' than FDA-approved estradiol 323127.
Why might a doctor prescribe compounded estriol?
Because no FDA-approved estriol product is marketed in the US, 503A compounding is the principal legal way for a US patient to receive estriol. Reasons documented by prescribing physicians include vaginal-atrophy symptoms where a vaginal estriol cream is desired (particularly when the patient has tolerated estriol in a European-market product), documented allergy or sensitivity to a component of an FDA-approved estradiol product, or a dose or formulation not commercially available 121. The compounded route is patient-specific, not direct-to-consumer 3326.
Can estriol be used in women with a history of breast cancer?
Vaginal estrogens, including low-dose vaginal estriol, in women with a history of breast cancer are treated as a shared-decision discussion involving the patient's treating oncologist. Hirschberg 2020 studied ultra-low-dose 0.005% estriol vaginal gel in postmenopausal breast-cancer survivors on aromatase inhibitors and reported improved vulvovaginal atrophy with low systemic estriol exposure, but the decision remains an individualized risk/benefit discussion 19. Major guidelines do not endorse vaginal estrogen use in this population as a default 2524.
Does RonanRx sell estriol directly to patients?
No. Compounded estriol is dispensed only on a patient-specific prescription written by a licensed doctor for an identified patient, with pharmacist review, ingredient-suitability verification, and lot-traceable preparation. RonanRx is not a direct-to-consumer storefront for estriol or for compounded Bi-Est / Tri-Est menopausal HT 33.
Clinician resource
Download the Estriol Clinical Monograph (PDF)
The full white paper covers every section on this page plus chemical identity, evidence grading, indication-by-indication summaries, research gaps, and reference appendix. Suitable for sharing with prescribing doctors and pharmacist reviewers.
[head1998] Head KA. Estriol: safety and efficacy. Alternative Medicine Review. 1998. PMID 9577246. (accessed 2026-05-11)
[kuhl2005] Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005. PMID 16112947. (accessed 2026-05-11)
[sicotte2002] Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Annals of Neurology. 2002. PMID 12325070. (accessed 2026-05-11)
[soldan2003] Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. Journal of Immunology. 2003. PMID 14634144. (accessed 2026-05-11)
[voskuhl2016] Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 2016. PMID 26621682. (accessed 2026-05-11)
[mackenzie2018] MacKenzie-Graham A, Brook J, Kurth F, et al. Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry. Brain and Behavior. 2018. PMID 30144306. (accessed 2026-05-11)
[voskuhl2022] Voskuhl R, Kuhle J, Siddarth P, et al. Decreased neurofilament light chain levels in estriol-treated multiple sclerosis. Annals of Clinical and Translational Neurology. 2022. PMID 35770318. (accessed 2026-05-11)
[spence2011] Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes. Proceedings of the National Academy of Sciences. 2011. PMID 21555578. (accessed 2026-05-11)
[spence2012] Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Frontiers in Neuroendocrinology. 2012. PMID 22209870. (accessed 2026-05-11)
[wisdom2013] Wisdom AJ, Cao Y, Itoh N, et al. Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. Journal of Neuroscience Research. 2013. PMID 23633287. (accessed 2026-05-11)
[confavreux1998] Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. New England Journal of Medicine. 1998. PMID 9682040. (accessed 2026-05-11)
[takahashi2000a] Takahashi K, Manabe A, Okada M, et al. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas. 2000. PMID 10714912. (accessed 2026-05-11)
[takahashi2000b] Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Human Reproduction. 2000. PMID 10783346. (accessed 2026-05-11)
[granberg2002] Granberg S, Eurenius K, Lindgren R, Wilhelmsson L. The effects of oral estriol on the endometrium in postmenopausal women. Maturitas. 2002. PMID 12065174. (accessed 2026-05-11)
[henriksson1994] Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. American Journal of Obstetrics and Gynecology. 1994. PMID 8092207. (accessed 2026-05-11)
[caruso2016] Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016. PMID 26079974. (accessed 2026-05-11)
[caruso2017] Caruso S, Cianci S, Vitale SG, et al. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause. 2017. PMID 28350758. (accessed 2026-05-11)
[murina2016] Murina F, Graziottin A, Felice R, et al. Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2016. PMID 27838536. (accessed 2026-05-11)
[hirschberg2020] Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020. PMID 32049923. (accessed 2026-05-11)
[buchholz2015] Buchholz S, Mögele M, Lintermans A, et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 2015. PMID 25427450. (accessed 2026-05-11)
[lethaby2016] Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 2016. PMID 27577677. (accessed 2026-05-11)
[cardozo1998] Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. International Urogynecology Journal and Pelvic Floor Dysfunction. 1999. PMID 10430010. (accessed 2026-05-11)
[gupta2011] Yoo J, et al. Urinary tract infection in postmenopausal women. Korean Journal of Urology. 2011. PMID 22216390. (accessed 2026-05-11)
[crandall2023] Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023. PMID 36749328. (accessed 2026-05-11)
[nams2017] The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017. PMID 28650869. (accessed 2026-05-11)
[nasem2020] Pinkerton JV, Faubion SS, Kaunitz AM, et al. The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy. Menopause. 2020. PMID 33110032. (accessed 2026-05-11)
[acog2012] Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion No. 532: compounded bioidentical menopausal hormone therapy. Obstetrics and Gynecology. 2012. PMID 22825109. (accessed 2026-05-11)
[pinkerton2014] Pinkerton JV. Think twice before prescribing custom-compounded bioidentical hormone therapy. Journal of Women's Health. 2014. PMID 25111854. (accessed 2026-05-11)
[pinkerton2016] Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause. 2016. PMID 26418479. (accessed 2026-05-11)
[pinkerton2022] Pinkerton JV. Concerns About Compounded Bioidentical Menopausal Hormone Therapy. Cancer Journal. 2022. PMID 35594471. (accessed 2026-05-11)
[boothby2004] Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004. PMID 15167316. (accessed 2026-05-11)
[files2011] Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clinic Proceedings. 2011. PMID 21531972. (accessed 2026-05-11)
Compounded Estriol is dispensed under 503A on a patient-specific prescription. Pick the path that matches where you're starting from.
For doctors
Offer this medication.
A pharmacist will follow up within two business days. We'll cover state availability, supported formulations, and what integration looks like for your clinic.
If your doctor has already prescribed Estriol, sign up so we can prepare and ship your medication. The signup wizard collects intake and connects you to the prescribing workflow.
RonanRx prescribes through partner clinics — we don't initiate prescriptions on this site. See how the referral works and how to find a clinic in your state that has evaluated patients for Estriol.
